Navigation Links
Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease
Date:10/14/2008

- Five research teams selected to receive funding for preclinical and

clinical research projects in Parkinson's disease-related cognitive

deficits and mood disorders

ROCKLAND, Mass., Oct. 14 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded a total of $2 million to five research teams to speed development of effective therapies for the under-addressed cognitive and mood-related symptoms of Parkinson's disease (PD). The award was made possible by leadership funding from EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany.

The research grants will support preclinical and clinical projects under MJFF's Cognitive Deficits and Mood Disorders in Parkinson's Disease initiative. Patients often report these symptoms, which range from problems with executive function (the ability to formulate, sequence, and execute plans) to dementia; depression, apathy and anxiety; and behavioral issues including problems with impulse control, to be among the most difficult aspects of living with PD.

"Clinicians and patients alike report how disabling the cognitive and mood effects of PD can be, yet these symptoms are systematically under-researched and are poorly understood," said Katie Hood, CEO of The Michael J. Fox Foundation. "We are thrilled to have found a like-minded partner in EMD Serono so that we can push this work forward."

Elmar Schnee, Merck's Executive Board Member responsible for Pharmaceuticals, said: "We recognize the critical need for new therapies to alleviate PD-related cognitive dysfunction. We are pleased to stand side by side with The Michael J. Fox Foundation in prioritizing and supporting research with potential to help speed development of effective treatments that will allow every patient to live a fuller and more satisfying life."

The development of treatments for cognitive and mood symptoms of PD has been hindered by a lack of preclinical models to explain these features of the disease; a lack of basic knowledge of the mechanisms that underlie these symptoms; inadequate understanding of the clinical features of these symptoms in PD; and a need for relevant clinical scales to improve diagnosis and for use as tools in clinical intervention trials. Funded teams will pursue approaches within each of these areas to improve the field's ability to model and test interventions for these symptoms.

Eugenia Gurevich, PhD, of Vanderbilt University (USA) will test the hypothesis that simultaneous reduction of dopamine and the neurotransmitter acetylcholine, which plays a major role in memory formation, leads to symptoms of PD-related dementia. To test this hypothesis, her group will administer a Parkinsonian toxin to preclinical models with lowered levels of acetylcholine, then measure their performance on a battery of cognitive tests. If the preclinical models show cognitive impairment, this project could lead to the identification of a novel preclinical model for testing therapeutic strategies for the cognitive symptoms of PD.

John Growdon, MD, of Harvard University (USA) will build on preliminary data implicating the protein beta amyloid -- better known for its role in Alzheimer's disease -- in PD-related cognitive changes. Dr. Growdon will enroll 40 PD patients, half of whom are experiencing cognitive impairment. Working with Pittsburgh compound B (PIB), an imaging agent developed by Alzheimer's researchers to visualize amyloid protein accumulation in the living brain, Dr. Growdon's team will scan the PD patients' brains. The researchers will then follow this cohort of patients over a two-year period to determine the extent of cognitive changes undergone by each and correlate this data to the scans. The work could lead to the initial validation of amyloid as a therapeutic target of interest and potential biomarker for PD-related cognitive decline.

Ben Schmand, PhD, of Academic Medical Center (The Netherlands) has been funded to extend an observational clinical study begun three years ago. His study has thus far collected a wealth of information on parkinsonism, neuropsychological status and quality of life. Dr. Schmand, who began his study with 120 people with PD and 70 controls, will now follow the remaining cohort of 90 patients and 60 controls with the objective of identifying early predictors of cognitive decline. Because preliminary data suggest that 20 percent of enrolled PD patients exhibited early cognitive impairment not observed in controls, extending the study should help detect further changes that will increase understanding of the phenomenology of cognitive changes in PD.

Connie Marras, MD, PhD, of the University of Toronto (Canada) will work to validate a well-known test for cognitive impairment, the Montreal Cognitive Assessment (MoCA), for diagnosing PD-related cognitive changes. Currently available tests for detecting cognitive impairment are either insensitive to the specific changes that occur in PD, test only some of the brain functions that can be impaired in PD-related dementia, and/or can be highly time-consuming. The MoCA, which takes less than 10 minutes to administer, could offer a wider window for detecting changes in PD patients. Dr. Marras will enroll 140 PD patients to take the MoCA questionnaire, whom she will then follow over time to determine the ability of MoCA to detect cognitive impairment in PD. Validation of the MoCA will provide a critical research tool needed to improve diagnosis of PD cognitive changes as well as for testing of novel therapeutics in future clinical trials.

Celeste Napier, PhD, of Rush University (USA) will work to shed light on the pathological gambling and other problems with impulse control that may be linked to dopamine replacement therapy in PD. While dopamine is involved with both the motor and reward systems, it is unclear why some PD patients exhibit reward-seeking behavior, particularly when taking dopaminergic drugs. Dr. Napier will combine preclinical models of PD and addictive behavior with the goal of developing a preclinical model to better characterize the putative link between dopamine replacement and impulse control problems.

Awards duration ranges from one to three years. As with all MJFF grants, full funding is dependent on fulfillment of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the PD research community. The selection of program awardees was made exclusively by the Foundation under its standard peer-review process.

The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded $128 million in research to date.

About EMD Serono

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R) (somatropin (rDNA origin) for injection), Serostim(R) (somatropin (rDNA origin) for injection) and Zorbtive(TM) (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 950 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit http://www.emdserono.com

About Merck KGaA

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.1 billion in 2007, a history that began in 1668, and a future shaped by 30,968 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit http://www.merckserono.net or http://www.merck.de


'/>"/>
SOURCE EMD Serono, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Bioethics International, a not-for-profit organization focused on the ethics ... made accessible to patients around the world, today announced that ... publication of the Good Pharma Scorecard an ... as one of BMJ Open ,s ,Most Popular Articles, ... most frequently read. Ed Sucksmith , assistant editor ...
(Date:2/11/2016)... 11, 2016  Wellcentive today announced it has ... Oregon -based community care organization (CCO) with ... analytics, quality reporting and care management solutions and ... team of quality managers, analysts and care managers ... groups serving FamilyCare members. ...
(Date:2/11/2016)... , Feb. 11, 2016  Dovetail Genomics™ LLC today ... beta program for a planned metagenomic genome assembly service. ... company,s metagenomic genome assembly method in a talk on ... Biology & Technology conference in Orlando, Fla. ... highly complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
Breaking Biology Technology:
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
(Date:1/21/2016)... --> ... report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, NLP, ... Voice Recognition and Others), Services, Application Areas, End ... published by MarketsandMarkets, the global Emotion Detection and ... Billion by 2020, at a CAGR of 31.9%, ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... MedNet,s significant achievements are the result of the company,s ... iMedNet eClinical , it,s comprehensive, easy-to-use and ... --> Key MedNet growth achievements in ...
Breaking Biology News(10 mins):